A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

This study is testing whether a PET imaging agent called PYLARIFY (piflufolastat F-18) — originally approved to detect the spread of prostate cancer — can also help visualize certain other solid tumors that express a protein called PSMA (prostate-specific membrane antigen). The goal is to explore whether this scan could be useful across a broader range of cancers. **You may be eligible if...** - You are 18 or older - You have been diagnosed with a solid tumor cancer (not prostate) that may express the PSMA protein - Your doctor believes a PET scan may provide useful staging or restaging information **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have contraindications to PET imaging - Your tumor type is unlikely to express the PSMA protein that PYLARIFY targets Talk to your doctor to see if this trial is right for you.